EUVIMEDEUVIMED entdecken
Crossref

Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing

Lauren Fairchild iD, Jeanne Whalen, Katie D'Aco iD, Jincheng Wu, Carroll B Gustafson, Nadia Solovieff, Fei Su, Rebecca J Leary iD, Catarina D Campbell iD, O Alejandro Balbin iD

Science Translational Medicine · 29.03.2023 · 15 (689)

DOI: 10.1126/scitranslmed.abm8729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 29.03.2023. Verfasst von Lauren Fairchild und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA sequencing alone, applying our model to 4324 oncology clinical cfDNA samples. Using this method, we determined that 30.3% of patients in this cohort have evidence of CH, and the incidence of CH varies by tumor type. Matched RNA sequencing data show evidence of increased inflammation, especially neutrophil activation, within the tumors and tumor microenvironments of patients with CH. In addition, patients with CH had evidence of neutrophil activation systemically, pointing to a potential mechanism of action for the worse outcomes associated with CH status. Neutrophil activation may be one of many mechanisms, however, because patients with estrogen receptor–positive breast cancer harboring TET2 frameshift mutations had worse outcomes but similar neutrophil frequencies to patients without CH. Together, these data show the feasibility of detecting CH through cfDNA sequencing alone and an application of this method, demonstrating increased inflammation in patients with CH both systemically and in the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsNeoplasmsHumansClonal HematopoiesisHematopoiesisInflammationSequence Analysis, DNAMutationTumor Microenvironment

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

ORCID-Profile: Lauren Fairchild, Katie D'Aco, Rebecca J Leary, Catarina D Campbell, O Alejandro Balbin

Zitieren

APA

Fairchild, L., Whalen, J., D'Aco, K., Wu, J., Gustafson, C. B., Solovieff, N., Su, F., Leary, R. J., Campbell, C. D., & Balbin, O. A. (2023). Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Science Translational Medicine, 15(689). https://doi.org/10.1126/scitranslmed.abm8729

Vancouver

Fairchild L, Whalen J, D'Aco K, Wu J, Gustafson CB, Solovieff N, et al. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Science Translational Medicine. 2023;15(689). doi:10.1126/scitranslmed.abm8729

BibTeX
@article{Fairchild2023,
  author = {Fairchild, Lauren and Whalen, Jeanne and D'Aco, Katie and Wu, Jincheng and Gustafson, Carroll B and Solovieff, Nadia and Su, Fei and Leary, Rebecca J and Campbell, Catarina D and Balbin, O Alejandro},
  title = {Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {689},
  doi = {10.1126/scitranslmed.abm8729}
}
Kostenlos starten →